Are there any benefits of Betoptic® S(betaxolol HCl ophthalmic suspension) over other β-blockers in the treatment of glaucoma?

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 5, 2004, Pages 1071-1081

  Yarangümeli, Alper ^a,b   Kural, Gülcan ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

blockers; Betaxolol; Glaucoma

Indexed keywords

ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BETOPTIC S; BUNOLOL; CALCIUM CHANNEL L TYPE; CARTEOLOL; DIPIVEFRINE; LEVOBUNOLOL; METIPRANOLOL; PLACEBO; POLYACRYLIC ACID; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG; EYE DROPS;

AIRWAY OBSTRUCTION; ANXIETY DISORDER; AQUEOUS HUMOR; BLEPHARITIS; BLOOD BRAIN BARRIER; BRADYCARDIA; BRONCHOSPASM; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; CHANNEL GATING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; DEPRESSION; DISORIENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TRANSPORT; DRY EYE; EYE BURNING; EYE IRRITATION; FATIGUE; GLAUCOMA; HEART ARRHYTHMIA; HEART BLOCK; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; KERATOPATHY; LUNG DISEASE; MENTAL INSTABILITY; NEUROPROTECTION; RECEPTOR OCCUPANCY; RETINA BLOOD FLOW; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYSTEMIC CIRCULATION; TREATMENT OUTCOME; VISUAL DISORDER; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; BETAXOLOL; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; RANDOMIZED CONTROLLED TRIALS; SUSPENSIONS;

EID: 2542620009     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/eoph.5.5.1071.31092     Document Type: Review

References (125)

1. BERROSPI AR, LEIBOWITZ HM: Betaxolol. A new beta-adrenergic blocking agent for treatment of glaucoma. Arch. Ophthalmol. (1982) 100(6):943-946.
2. WEINREB RN, VAN BUSKIRK EM, CHERNIACK R, DRAKE MM: Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am. J. Ophthalmol. (1988) 106(2):162-167.
3. RADIUS RL: Use of betaxolol in the reduction of elevated intraocular pressure. Arch. Ophthalmol. (1983) 101(6):898-900.
4. CALDWELL DR, SALISBURY CR, GUZEK JP: Effects of topical betaxolol in ocular hypertensive patients. Arch. Ophthalmol. (1984) 102(4):539-540.
5. FEGHALI JG, KAUFMAN PL: Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist. Am. J. Ophthalmol. (1985) 100(6):777-782.
6. HOSTE AM, SYS SU: Ca2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J. Cardiovasc. Pharmacol. (1998) 32(3):390-396.
7. TURACLI ME, OZDEN RG, GURSES MA: The effect of betaxolol on ocular blood flow and visual fields in patients with normotension glaucoma. Eur. J. Ophthalmol. (1998) 8(2):62-66.
8. HARRIS A, SPAETH GL, SERGOTT RC, KATZ LJ, CANTOR LB, MARTIN BJ: Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am. J. Ophthalmol. (1995) 120(2):168-175.
9. DRANCE SM: A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J. Glaucoma. (1998) 7(4):247-252.
10. BRON AJ, CHIDLOW G, MELENA J, OSBORNE NN: Beta-blockers in the treatment of glaucoma. In: Pharmacotherapy in Glaucoma. Orgül S, Flammer J (Eds), Verlag Hans Huber, Bern, Switzerland (2000):79-113.
11. NATHANSON JA: Human ciliary process adrenergic receptor: pharmacological characterization. Invest. Ophthalmol. Vis. Sci. (1981) 21(6):798-804.
12. WAX MB, MOLINOFF PB: Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. Invest. Ophthalmol. Vis. Sci. (1987) 28(3):420-430.
13. NEUFELD AH, JAMPOL LM, SEARS ML: Cydic-AMP in the aqueous humor: the effects of adrenergic agents. Exp. Eye Res. (1972) 14(3):242-250.
14. TOWNSEND DJ, BRUBAKER RF: Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest. Ophthalmol. Vis. Sci. (1980) 19(3):256-266.
15. WAX MB, MOLINOFF PB, ALVARADO J, POLANSKY J: Characterization of beta-adrenergic receptors in cultured human trabecular cells and in human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. (1989) 30(1):51-57.
16. WIEDERHOLT M: Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. Curr. Opin. Ophthalmol. (1998) 9(2):46-49.
17. PHILLIPS CI. HOWITT G, ROWLANDS DJ: Propranolol as ocular hypotensive agent. Br. J. Ophthalmol. (1967) 51(4):222-226.
18. MUSINI A, FABBRI B, BERGAMASCHI M, MANDELLI V, SHANKS RG: Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am. J. Ophthalmol. (1971) 72(4):773-781.
19. ZIMMERMAN TJ, KAUFMAN HE: Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol. (1977) 95(4):601-604.
20. NEUFELD AH: Experimental studies on the mechanism of action of timolol. Surv. Ophthalmol. (1979) 23(6):363-370.
21. TOPPER JE, BRUBAKER RF: Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest. Ophthalmol. Vis. Sci. (1985) 26(10):1315-1319.
22. REISS GR, LEE DA, TOPPER JE, BRUBAKER RF: Aqueous humor flow during sleep. Invest. Ophthalmol. Vis. Sci. (1984) 25(6):776-778.
23. MAUS TL, MCLAREN JW, SHEPARD JW Jr, BRUBAKER RF: The effects of sleep on circulating catecholamines and aqueous flow in human subjects. Exp. Eye Res. (1996) 62(4):351-358.
24. BRUBAKER RF: Flow of aqueous humor in humans. The Friedenwald Lecture. Invest. Ophthalmol. Vis. Sci. (1991) 32(13):3145-3166.
25. SONNTAG JR, BRINDLEY GO, SHIELDS MB: Effect of timolol therapy on outflow facility. Invest. Ophthalmol. Vis. Sci. (1978) 17(3):293-296.
26. THOMAS JV, EPSTEIN DL: Timolol and epinephrine in primary open angle glaucoma. Transient additive effect. Arch. Ophthalmol. (1981) 99(1):91-95.
27. NYBORG NC, NIELSEN PJ: Beta-adrenergic receptors regulating vascular smooth muscle tone are only localized to the intraocular segment of the long posterior ciliary artery in bovine eye. Surv. Ophthalmol. (1995) 39(Suppl. 1):S66-S75.
28. VAN BUSKIRK EM, BACON DR, FAHRENBACH WH: Ciliary vasoconstriction after topical adrenergic drugs. Am. J. Ophthalmol. (1990) 109(5):511-517.
29. GROH MJ, MICHELSON G, GROH ME, GRUNDLER AE: Ocular macro- and microcirculation after topical application of clonidine and metipranolol. Ger. J. Ophthalmol. (1994) 3(3):175-178.
30. GEISER SC, JUZYCH M, ROBIN A, SCHWARTZ GF: Clinical pharmacology of adrenergic drugs. In: The Glaucomas (Vol. 3). Glaucoma therapy. Ritch R, Shields MB, Krupin T (Eds), Mosby-Year Book Inc, St. Louis, USA (1996):1425-1448.
31. ZIMMERMAN TJ, KAUFMAN HE: Timolol, dose response and duration of action. Arch. Ophthalmol. (1977) 95(4):605-607.
32. ZIMMERMAN TJ, KASS MA, YABLONSKI ME, BECKER B: Timolol maleate: efficacy and safety. Arch. Ophthalmol. (1979) 97(4):656-658.
33. RADIUS RL, DIAMOND GR, POLLACK IP, LANGHAM ME: Timolol. A new drug for management of chronic simple glaucoma. Arch. Ophthalmol. (1978) 96(6):1003-1008.
34. STEINBACH PD: Pressure-lowering effect of timolol in various forms of glaucoma. Klin. Monatsbl. Augenheilkd. (1980) 176(5):844-845.
35. KATZ IM, BERGER ET: Effects of iris pigmentation on response of ocular pressure to timolol. Surv. Ophthalmol. (1979) 23(6):395-398.
36. SCHLECHT LP, BRUBAKER RF: The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology (1988) 95(9):1212-1216.
37. BOGER WP 3RD: Shortterm, escape and longterm drift. The dissipation effects of the beta adrenergic blocking agents. Surv. Ophthalmol. (1983) 28(Suppl.):235-242.
38. STEINERT RF, THOMAS JV, BOGER WP 3rd: Long-term drift and continued efficacy after multiyear timolol therapy. Arch. Ophthalmol. (1981) 99(1):100-103.
39. WOODWARD DF, NOVACK GD, WILLIAMS LS, NIEVES AL, POTTER DE: Dihydrolevobunolol is a potent ocular beta-adrenoceptor antagonist. J. Ocul. Pharmacol. (1987) 3(1):11-15.
40. GEYER O, LAZAR M, NOVACK GD, SHEN D, ETO CY: Levobunolol compared with timolol: a four-year study. Br. J. Ophthalmol. (1988) 72(12):892-896.
41. THE LEVOBUNOLOL STUDY GROUP: Levobunolol. A four-year study of efficacy and safety in glaucoma treatment. Ophthalmology (1989) 96(5):642-645.
42. KRUSE W: Metipranolol: a new beta-blocker. Klin. Monatsbl. Augenheilkd. (1983) 182(6):582-584.
43. SERLE JB, LUSTGARTEN JS, PODOS SM: A clinical trial of metipranolol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension. Am. J. Ophthalmol. (1991) 112(3):302-307.
44. ALLEN RC: Medical management of glaucoma. In: Principles and Practice of Ophthalmology (Vol. 3, Section 7). Glaucoma. Albert DM, Jacobiec EA (Eds), WB Saunders Company, Philadelphia, USA (1994):1569-1588.
45. MILLS KB, WRIGHT G: A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study. Br. J. Ophthalmol. 1986 70(1):39-42.
46. KRIEGLSTEIN GK, NOVACK GD, VOEPEL E et al.: Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. Br. J. Ophthalmol. (1987) 71(4):250-253.
47. JASPER JR, MICHEL MC, INSEL PA: The beta-adrenoceptor antagonist carteolol and its metabolite 8-hydroxycarteolol have different intrinsic sympathomimetic activities. Br. J. Clin. Pharmacol. (1990) 30(Suppl. 1):109S-111S.
48. STEWART WC, SHIELDS MB, ALLEN RC et al.: A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. (1991) 229(3):258-261.
49. STEWART WC, COHEN JS, NETLAND PA, WEISS H, NUSSBAUM LL: Efficacy of carteolol hydrochloride 1% versus timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am. J. Ophthalmol. (1997) 124(4):498-505.
50. WANDEL T, FISHMAN D, NOVACK GD, KELLEY E, CHEN KK: Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily. Ophthalmology (1988) 95(2):252-255.
51. SHELL JW: Pharmacokinetics of topically applied ophthalmic drugs. Surv. Ophthalmol. (1982) 26(4):207-218.
52. VAN BUSKIRK EM: Adverse reactions from timolol administration. Ophthalmology (1980) 87(5):447-450.
53. VAN BUSKIRK EM: Corneal anesthesia after timolol maleate therapy. Am. J. Ophthalmol. (1979) 88(4):739-743.
54. TURACLI E, BUDAK K, KAUR A, MIZRAK B, EKINCI C: The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int. Ophthalmol. (1997) 21(1):27-33.
55. CVENKEL B, IHAN A: Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica (2002) 216(3):175-179.
56. AKINGBEHIN T, VILLADA JR: Metipranolol-associated granulomatous anterior uveitis. Br. J. Ophthalmol. (1991) 75(9):519-523.
57. MELLES RB, WONG IG: Metipranolol-associated granulomatous iritis. Am. J. Ophthalmol. (1994) 118(6):712-715.
58. DUCH S, DUCH C, PASTO L, FERRER P: Changes in depressive status associated with topical beta-blockers. Int. Ophthalmol. (1992) 16(4-5):331-335.
59. LYNCH MG, WHITSON JT, BROWN RH, NGUYEN H, DRAKE MM: Topical beta-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol. Arch. Ophthalmol. (1988) 106(7):908-911.
60. NETLAND PA, WEISS HS, STEWART WC, COHEN JS, NUSSBAUM LL: Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am. J. Ophthalmol. (1997) 123(4):465-477.
61. FREEDMAN SF, FREEDMAN NJ, SHIELDS MB et al.: Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am. J. Ophthalmol. (1993) 116(5):600-611.
62. STEWART WC, DUBINER HB, MUNDORF TK et al.: Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am. J. Ophthamol. (1999) 127(2):142-147.
63. LE JEUNNE CL, HUGUES FC, DUFIER JL, MUNERA Y, BRINGER L: Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J. Clin. Pharmacol. (1989) 29(2):97-101.
64. BERRY DP JR, VAN BUSKIRK EM, SHIELDS MB: Betaxolol and timolol. A comparison of efficacy and side effects. Arch. Ophthalmol. (1984) 102(1):42-45.
65. ALLEN RC, HERTZMARK E, WALKER AM, EPSTEIN DL: A double-masked comparison of betaxolol versus timolol in the treatment of open-angle glaucoma. Am. J. Ophthalmol. (1986) 101(5):535-541.
66. STEWART RH, KIMBROUGH RL, WARD RL: Betaxolol versus timolol. A six-month double-blind comparison. Arch. Ophthalmol. (1986) 104(1):46-48.
67. LONG DA, JOHNS GE, MULLEN RS et al.: Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure. Ophthalmology (1988) 95(6):735-741.
68. REISS GR, BRUBAKER RF: The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology (1983) 90(11):1369-1372.
69. PHAN TM, NGUYEN KP, GIACOMINI JC, LEE DA: Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. J. Ocul. Pharmacol. (1991) 7(3):243-252.
70. GAUL GR, WILL NJ, BRUBAKER RF: Comparison of a noncardioselective beta-adrenoceptor blocker and a cardioselective blocker in reducing aqueous flow in humans. Arch. Ophthalmol. (1989) 107(9):1308-1311.
71. MARTIN X: Mechanism of action of beta-blockers. Ophtalmologie (1990) 4(2):154-155.
72. OSBORNE NN, CHIDLOW G: Do beta-adrenoceptors and serotonin 5-HT1A receptors have similar functions in the control of intraocular pressure in the rabbit? Ophthalmologica (1996) 210(5):308-314.
73. ROBINSON JC, KAUFMAN PL: Effects and interactions of epinephrine, norepinephrine, timolol, and betaxolol on outflow facility in the cynomolgus monkey. Am. J. Ophthalmol. (1990) 109(2):189-194.
74. ALLEN RC, EPSTEIN DL: Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Arch. Ophthalmol. (1986) 104(8):1178-1184.
75. WEINREB RN, RITCH R, KUSHNER FH: Effect of adding betaxolol to dipivefrin therapy. Am. J. Ophthalmol. (1986) 101(2):196-198.
76. ZIMMERMAN TJ: Topical ophthalmic beta blockers: a comparative review. J. Ocul. Pharmacol (1993) 9(4):373-384.
77. WALDOCK A, SNAPE J, GRAHAM CM: Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br. J. Ophthalmol. (2000) 84(7):710-713.
78. YAMADA Y, TAKAYANAGI R, TSUCHIYA K et al.: Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J. Ocul. Pharmacol. Ther. (2001) 17(3):235-248.
79. HAYREH SS, PODHAJSKY P, ZIMMERMAN MB: Beta-blocker eyedrops and nocturnal arterial hypotension. Am. J. Ophthalmol. (1999) 128(3):301-309.
80. ATKINS JM, PUGH BR JR, TIMEWELL RM: Cardiovascular effects of topical beta-blockers during exercise. Am. J. Ophthalmol. (1985) 99(2):173-175.
81. AREND O, HARRIS A, AREND S, REMKY A, MARTIN BJ: The acute effect of topical beta-adrenoreceptor blocking agents on retinal and optic nerve head circulation. Acta. Ophthalmol. Scand. (1998) 76(1):43-49.
82. BALL S: Congestive heart failure from betaxolol. Case report. Arch. Ophthalmol. (1987) 105(3):320.
83. ZABEL RW, MACDONALD IM: Sinus arrest associated with betaxolol ophthalmic drops. Am. J. Ophthalmol. (1987) 104(4):431.
84. VAN BUSKIRK EM, WEINREB RN, BERRY DP, LUSTGARTEN JS, PODOS SM, DRAKE MM: Betaxolol in patients with glaucoma and asthma. Am. J. Ophthalmol. (1986) 101(5):531-534.
85. GOLDBERG I, GOLDBERG H: Betaxolol eye drops. A clinical trial of safety and efficacy. Aust. AZ J. Ophthalmol. (1995) 23(1):17-24.
86. SCHOENE RB, ABUAN T, WARD RL, BEASLEY CH: Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am. J. Ophthalmol. (1984) 97(1):86-92.
87. DIGGORY P, CASSELS-BROWN A, FERNANDEZ C: Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Age Ageing (1996) 25(6):424-428.
88. HARRIS LS, GREENSTEIN SH, BLOOM AF: Respiratory difficulties with betaxolol. Am. J. Ophthalmol. (1986) 102(2):274-275.
89. ROHOLT PC: Betaxolol and restrictive airway disease. Case report. Arch. Ophthalmol. (1987) 105(9):1172.
90. MESSMER C, FLAMMER J, STUMPFIG D: Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am. J. Ophthalmol. (1991) 112(6):678-681.
91. COLLIGNON-BRACH J: Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Curr. Eye Res. (1992) 11(1):1-3.
92. KAISER HJ, FLAMMER J, STUMPFIG D, HENDRICKSON P: Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv. Ophthalmol. (1994) 38(Suppl.):S156-159.
93. VAINIO-JYLHA E, VUORI ML: The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Graefes Arch. Clin. Exp. Ophthalmol. (1999) 237(2):100-104.
94. ARAIE M, AZUMA I, KITAZAWA Y: Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients. Jpn. J. Ophthalmol. (2003) 47(2):199-207.
95. WATSON PG, BARNETT MF, PARKER V, HAYBITTLE J: A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br. J. Ophthalmol. (2001) 85(8):962-968.
96. ORGUL S, MANSBERGER S, BACON DR, VAN BUSKIRK EM, CIOFFI GA: Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits. Am. J. Ophthalmol. (1995) 120(4):441-447.
97. COLLIGNON NJ, COLLIGNON-BRACH JD: Effect of topical betablockers on human retinal vessels diameters. Int. Ophthalmol. (1997-1998) 21(4):199-203.
98. YU DY, SU EN, CRINGLE SJ, ALDER VA, YU PK, DESANTIS L: Effect of betaxolol, timolol and nimodipine on human and pig retinal arterioles. Exp. Eye Res. (1998) 67(1):73-81.
99. SCHMETTERER L, STRENN K, FINDL O et al.: Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin. Pharmacol. Ther. (1997) 61(5):583-595.
100. HARRIS A, AREND O, CHUNG HS, KAGEMANN L, CANTOR L, MARTIN B: A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Ophthalmology (2000) 107(3):430-434.
101. STEIGERWALT RD Jr, LAURORA G, BELCARO GV et al.: Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. J. Ocul. Pharmacol. Ther. (2001) 17(6):537-544.
102. ARAIE M, MUTA K: Effect of long-term topical betaxolol on tissue circulation in the iris and optic nerve head. Exp. Eye Res. (1997) 64(2):167-172.
103. TAMAKI Y, ARAIE M, TOMITA K, NAGAHARA M: Effect of topical betaxolol on tissue circulation in the human optic nerve head. J. Ocul. Pharmacol. Ther. (1999) 15(4):313-321.
104. YOSHIDA A, OGASAWARA H, FUJIO N et al.: Comparison of short- and long-term effects of betaxolol and timolol on human retinal circulation. Eye (1998) 12(5):848-853.
105. HAEFLIGER IO, LIETZ A, GRIESSER SM et al.: Modulation of Heidelberg Retinal Flowmeter parameter flow at the papilla of healthy subjects: effect of carbogen, oxygen, high intraocular pressure, and beta-blockers. Surv. Ophthalmol. (1999) 43(Suppl. 1):S59-S65.
106. RAINER G, DORNER GT, GARHOFER G, VASS C, PFLEGER T, SCHMETTERER L: Changing antiglaucoma therapy from timolol to betaxolol: effect on ocular blood flow. Ophthalmologica. (2003) 217(4):288-293.
107. HOSTE AM: In vitro studies of the effects of beta-adrenergic drugs on retinal and posterior ciliary microarteries. Surv. Ophthalmol. (1999) 43(Suppl. 1):S183-S190.
108. HESTER RK, CHEN Z, BECKER EJ, MCLAUGHLIN M, DESANTIS L: The direct vascular relaxing action of betaxolol, carteolol. and timolol in porcine long posterior ciliary artery. Surv. Ophthalmol. (1994) 38(Suppl.):S125-S134.
109. YU DY, SU EN, CRINGLE SJ, ALDER VA, YU PK, DESANTIS L: Systemic and ocular vascular roles of the antiglaucoma agents beta-adrenergic antagonists and Ca2+ entry blockers. Surv. ophthalmoL. (1999) 43(Suppl. 1):S214-S222.
110. RANDALL MD: Vascular activities of the endothelins. Pharmacol. Ther. (1991) 50(1):73-93.
111. KIM JH, KIM DM, PARK WC: Effect of betaxolol on impaired choroidal blood flow after intravitreal injection of endothelin-1 in albino rabbits. J. Ocul. Pharmacol. Ther. (2002) 18(3):203-209.
112. OSBORNE NN, UGARTE M, CHAO M et al.: Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol. (1999) 43(Suppl. 1):S102-S128.
113. NICKELLS RW. Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv. Ophthalmol. (1999) 43(Suppl. 1):S151-161.
114. DREYER EB, ZURAKOWSKI D, SCHUMER RA, PODOS SM, LIPTON SA: Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmal. (1996) 114(3):299-305.
115. OSBORNE NN, CAZEVIEILLE C, CARVALHO AL, LARSEN AK, DESANTIS L: In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. (1997) 751(1):113-123.
116. HIROOKA K, KELLY ME, BALDRIDGE WH, BARNES S: Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp. Eye Res. (2000) 70(5):611-621.
117. ZHANG J, WU SM, GROSS RL: Effects of beta-adrenergic blockers on glutamate-induced calcium signals in adult mouse retinal ganglion cells. Brain Res. (2003) 959(1):111-119.
118. WOOD JP, SCHMIDT KG, MELENA J, CHIDLOW G, ALLMEIER H, OSBORNE NN: The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. (2003) 76(4):505-516.
119. WOOD JP, DESANTIS L, CHAO HM, OSBORNE NN: Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. (2001) 72(1):79-86.
120. AGARWAL N, MARTIN E, KRISHNAMOORTHY RR et al.: Levobetaxolol-induced up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy. Exp. Eye Res. (2002) 74(4):445-453.
121. CHIDLOW G, MELENA J, OSBORNE NN: Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br. J. Pharmacol. (2000) 130(4):759-766.
122. OSBORNE NN, DESANTIS L, BAE JH et al.: Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. (1999) 69(3):331-342.
123. WEINREB RN, JANI R: A novel formulation of an ophthalmic beta-adrenoceptor antagonist. J. Parenter. Sci. Technol. (1992) 46(2):51-53.
124. WEINREB RN, CALDWELL DR, GOODE SM et al.: A double-masked three-month comparison between 0.25% betaxolol suspension and0.5% betaxolol ophthalmic solution. Am. J. Ophthalmol. (1990) 110(2):189-192.
125. SACCA SC, MACRI A, ROLANDO M, CIURLO G: Effect of betaxolol on primary open-angle glaucoma and normal-tension glaucoma patients. J. Ocul. Pharmacol. Ther. (1998) 14(3):191-201.